- Home
- RNAC
as 05-30-2025 4:00pm EST
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 264.7M | IPO Year: | 2016 |
| Target Price: | $41.00 | AVG Volume (30 days): | 76.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.46 - $41.87 | Next Earning Date: | 05-08-2025 |
| Revenue: | $34,173,000 | Revenue Growth: | 31.91% |
| Revenue Growth (this year): | -90.78% | Revenue Growth (next year): | -93.74% |
Stock Insider Trading Activity of Cartesian Therapeutics Inc. (RNAC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Apr 9 '25 | Buy | $10.30 | 149,075 | $1,522,517.04 | 656,513 | |
| SPRINGER TIMOTHY A | RNAC | Director10% Owner | Mar 18 '25 | Buy | $14.99 | 89,863 | $1,371,154.37 | 656,513 |
Latest Cartesian Therapeutics Inc. News
RNAC Breaking Stock News: Dive into RNAC Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewswire
19 days ago
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Simply Wall St.
21 days ago
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St.
22 days ago
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations
GlobeNewswire
24 days ago
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
2 months ago
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire
2 months ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Compare RNAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAC Cartesian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.